Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medicinova (MNOV) Common Equity (2021 - 2025)

Medicinova (MNOV) has disclosed Common Equity for 7 consecutive years, with $41.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity changed N/A to $41.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $41.6 million, a N/A change, with the full-year FY2025 number at $41.6 million, changed N/A from a year prior.
  • Common Equity was $41.6 million for Q4 2025 at Medicinova, down from $44.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $92.4 million in Q1 2021 to a low of $41.6 million in Q4 2025.
  • A 5-year average of $66.5 million and a median of $64.9 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: decreased 11.54% in 2023, then decreased 20.16% in 2025.
  • Medicinova's Common Equity stood at $83.7 million in 2021, then fell by 12.63% to $73.1 million in 2022, then dropped by 14.67% to $62.4 million in 2023, then fell by 11.72% to $55.1 million in 2024, then dropped by 24.48% to $41.6 million in 2025.
  • Per Business Quant, the three most recent readings for MNOV's Common Equity are $41.6 million (Q4 2025), $44.0 million (Q3 2025), and $46.9 million (Q2 2025).